What is C2N Diagnostics?
C2N Diagnostics operates with a vision to bring Clarity Through Innovation in the brain health sector. The company provides specialized laboratory services and products crucial for clinical decision-making, aiming to improve patient diagnosis and treatment monitoring. Furthermore, C2N's offerings are instrumental in enhancing the quality and efficiency of clinical trials for novel neurodegeneration treatments. They also supply innovative tools to healthcare researchers, facilitating a deeper understanding of disease mechanisms, identification of new therapeutic targets, and the execution of vital epidemiologic studies to bolster global public health initiatives.
How much funding has C2N Diagnostics raised?
C2N Diagnostics has raised a total of $40M across 3 funding rounds:
Grant
$15M
Unspecified
$15M
Other Financing Round
$10M
Grant (2023): $15M with participation from GHR Foundation
Unspecified (2024): $15M led by us.eisai.com
Other Financing Round (2025): $10M supported by Samsung C&T
Key Investors in C2N Diagnostics
us.eisai.com
Eisai is a global pharmaceutical company committed to its human health care (hhc) mission, focusing on patients' needs and contributing to their well-being. Established in 1992, Eisai's innovation is driven by a deep understanding of patient needs, particularly in areas like neurodegenerative diseases.
GHR Foundation
GHR Foundation is dedicated to supporting transformational initiatives, with a focus on Alzheimer's prevention, global church vitality, thriving local communities, and Catholic higher education. They aim to foster early detection and treatment of Alzheimer's disease through strategic partnerships.
Samsung C&T
Samsung C&T, a significant entity in South Korea's service industry since 1938, operates across diverse sectors including resorts, fashion, trade, and engineering. Their involvement suggests a strategic interest in C2N Diagnostics' technological advancements and market potential.
What's next for C2N Diagnostics?
The recent major strategic investment signals a new phase of growth and development for C2N Diagnostics. This influx of capital is expected to accelerate the company's innovation pipeline, potentially expanding its biomarker services and product offerings. The strategic nature of this financing suggests a focus on scaling operations, forging key partnerships, and further solidifying its market position in the competitive brain health diagnostics landscape. C2N Diagnostics is poised to leverage this backing to drive advancements in Alzheimer's research and other neurodegenerative conditions, aiming to translate scientific discovery into tangible improvements in patient outcomes and clinical trial efficacy.
See full C2N Diagnostics company page
